Insider Buying Stocks
SGP is part of our Insider Buying Stocks list, indicating stock insiders are buying the stock.
NASDAQ:SGP • US85220G1094
The current stock price of SGP is 22.75 USD. Today SGP is down by -3.81%. In the past month the price increased by 4.6%.
SGP currently appears in the following ChartMill screener lists.
ChartMill assigns a technical rating of 3 / 10 to SGP.
ChartMill assigns a fundamental rating of 3 / 10 to SGP. No worries on liquidiy or solvency for SGP as it has an excellent financial health rating, but there are worries on the profitability.
9 analysts have analysed SGP and the average price target is 45.9 USD. This implies a price increase of 101.76% is expected in the next year compared to the current price of 22.75.
Over the last trailing twelve months SGP reported a non-GAAP Earnings per Share(EPS) of -2.5. The EPS decreased by -36.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.82% | ||
| ROE | -75.44% | ||
| Debt/Equity | 0 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 24.77 | 820.359B | ||
| JNJ | JOHNSON & JOHNSON | 17.97 | 542.756B | ||
| MRK | MERCK & CO. INC. | 21.74 | 272.255B | ||
| PFE | PFIZER INC | 8.92 | 152.391B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.18 | 117.972B | ||
| ZTS | ZOETIS INC | 16.54 | 49.567B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.65 | 28.645B | ||
| VTRS | VIATRIS INC | 5.92 | 17.245B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.12 | 11.031B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.586B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.117B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.111B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.93 | 4.916B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
SpyGlass Pharma Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Aliso Viejo, California and currently employs 65 full-time employees. The company went IPO on 2026-02-06. SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused in the development of the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The firm develops a non-bioerodible drug delivery technology, designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. Its lead product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System) is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma or ocular hypertension.
IPO: 2026-02-06
SPYGLASS PHARMA INC
27081 Aliso Creek Road, Suite 125
Aliso Viejo CALIFORNIA US
Employees: 65
Phone: 13026587581
SpyGlass Pharma Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Aliso Viejo, California and currently employs 65 full-time employees. The company went IPO on 2026-02-06. SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused in the development of the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The firm develops a non-bioerodible drug delivery technology, designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. Its lead product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System) is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma or ocular hypertension.
The current stock price of SGP is 22.75 USD. The price decreased by -3.81% in the last trading session.
SGP does not pay a dividend.
SGP has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
SGP stock is listed on the Nasdaq exchange.
SPYGLASS PHARMA INC (SGP) operates in the Health Care sector and the Pharmaceuticals industry.
The outstanding short interest for SPYGLASS PHARMA INC (SGP) is 3.22% of its float.